Tags

Type your tag names separated by a space and hit enter

Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
J Clin Lipidol. 2011 Nov-Dec; 5(6):483-92.JC

Abstract

BACKGROUND

Prescription omega-3-acid ethyl esters (POM3) reduce triglycerides (TG) and very low-density lipoprotein cholesterol and increase high-density lipoprotein cholesterol (HDL-C) in patients with hypertriglyceridemia.

OBJECTIVE

To examine the effects of POM3 plus atorvastatin versus placebo plus atorvastatin on lipoprotein particle concentrations and sizes, apolipoprotein (Apo) CIII, and lipoprotein-associated phospholipase A(2) mass in subjects with mixed dyslipidemia.

METHODS

After a 4-week diet lead in, men and women with non-HDL-C >160 mg/dL and TG 250-599 mg/dL, while taking no lipid-altering drugs, received double-blind 4 g/d POM3 (n = 118) or placebo (n = 119) with open-label atorvastatin 10 mg/d for 8 weeks, followed by escalation to 20 mg/d atorvastatin for 4 weeks, then 40 mg/d atorvastatin for 4 weeks.

RESULTS

Total low-density lipoprotein particle (LDL-P) concentration decreased significantly from baseline, and the reductions did not differ between the POM3 and placebo groups (-659.7 vs -624.4 nmol/L, P = .181). With POM3, compared with placebo, small LDL-P concentration decreased (P = .026), large LDL-P concentration increased (P < .001), mean LDL-P size increased (P = .001), a larger fraction of subjects switched from LDL subclass pattern B to A, and Apo CIII and lipoprotein-associated phospholipase A(2) levels were reduced (P < .001). The incremental effects of POM3 were similar across atorvastatin doses for most variables.

CONCLUSION

This analysis supports the view that LDL-P concentration is not increased by POM3 plus atorvastatin, relative to atorvastatin monotherapy, and is associated with potentially favorable shifts in LDL-P subfractions, Apo CIII and lipoprotein-associated phospholipase A(2) in mixed dyslipidemia.

Authors+Show Affiliations

Provident Clinical Research, Biofortis North America, Glen Ellyn, IL 60137, USA. KMaki@ProvidentCRC.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22108152

Citation

Maki, Kevin C., et al. "Effects of Prescription Omega-3-acid Ethyl Esters, Coadministered With Atorvastatin, On Circulating Levels of Lipoprotein Particles, Apolipoprotein CIII, and Lipoprotein-associated Phospholipase A2 Mass in Men and Women With Mixed Dyslipidemia." Journal of Clinical Lipidology, vol. 5, no. 6, 2011, pp. 483-92.
Maki KC, Bays HE, Dicklin MR, et al. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol. 2011;5(6):483-92.
Maki, K. C., Bays, H. E., Dicklin, M. R., Johnson, S. L., & Shabbout, M. (2011). Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. Journal of Clinical Lipidology, 5(6), 483-92. https://doi.org/10.1016/j.jacl.2011.09.001
Maki KC, et al. Effects of Prescription Omega-3-acid Ethyl Esters, Coadministered With Atorvastatin, On Circulating Levels of Lipoprotein Particles, Apolipoprotein CIII, and Lipoprotein-associated Phospholipase A2 Mass in Men and Women With Mixed Dyslipidemia. J Clin Lipidol. 2011 Nov-Dec;5(6):483-92. PubMed PMID: 22108152.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. AU - Maki,Kevin C, AU - Bays,Harold E, AU - Dicklin,Mary R, AU - Johnson,Susan L, AU - Shabbout,Mayadah, Y1 - 2011/09/13/ PY - 2011/06/27/received PY - 2011/08/16/revised PY - 2011/09/08/accepted PY - 2011/11/24/entrez PY - 2011/11/24/pubmed PY - 2012/3/13/medline SP - 483 EP - 92 JF - Journal of clinical lipidology JO - J Clin Lipidol VL - 5 IS - 6 N2 - BACKGROUND: Prescription omega-3-acid ethyl esters (POM3) reduce triglycerides (TG) and very low-density lipoprotein cholesterol and increase high-density lipoprotein cholesterol (HDL-C) in patients with hypertriglyceridemia. OBJECTIVE: To examine the effects of POM3 plus atorvastatin versus placebo plus atorvastatin on lipoprotein particle concentrations and sizes, apolipoprotein (Apo) CIII, and lipoprotein-associated phospholipase A(2) mass in subjects with mixed dyslipidemia. METHODS: After a 4-week diet lead in, men and women with non-HDL-C >160 mg/dL and TG 250-599 mg/dL, while taking no lipid-altering drugs, received double-blind 4 g/d POM3 (n = 118) or placebo (n = 119) with open-label atorvastatin 10 mg/d for 8 weeks, followed by escalation to 20 mg/d atorvastatin for 4 weeks, then 40 mg/d atorvastatin for 4 weeks. RESULTS: Total low-density lipoprotein particle (LDL-P) concentration decreased significantly from baseline, and the reductions did not differ between the POM3 and placebo groups (-659.7 vs -624.4 nmol/L, P = .181). With POM3, compared with placebo, small LDL-P concentration decreased (P = .026), large LDL-P concentration increased (P < .001), mean LDL-P size increased (P = .001), a larger fraction of subjects switched from LDL subclass pattern B to A, and Apo CIII and lipoprotein-associated phospholipase A(2) levels were reduced (P < .001). The incremental effects of POM3 were similar across atorvastatin doses for most variables. CONCLUSION: This analysis supports the view that LDL-P concentration is not increased by POM3 plus atorvastatin, relative to atorvastatin monotherapy, and is associated with potentially favorable shifts in LDL-P subfractions, Apo CIII and lipoprotein-associated phospholipase A(2) in mixed dyslipidemia. SN - 1933-2874 UR - https://www.unboundmedicine.com/medline/citation/22108152/Effects_of_prescription_omega_3_acid_ethyl_esters_coadministered_with_atorvastatin_on_circulating_levels_of_lipoprotein_particles_apolipoprotein_CIII_and_lipoprotein_associated_phospholipase_A2_mass_in_men_and_women_with_mixed_dyslipidemia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1933-2874(11)00710-0 DB - PRIME DP - Unbound Medicine ER -